Strategikon Announces Clinical Maestro 2.4
Strategikon Pharma announced a major update to their Clinical Maestro platform including features that target clinical trial planning and sourcing. This release, Clinical Maestro CORETM, focuses on expanding the ease of use and flexibility for Contract Research Organizations and other clinical service providers who need to quickly create accurate bids.
Clinical Maestro CORE is a configurable, cloud-based SaaS solution combining clinical study and services assumptions with complex costing algorithms that aim to produce clinical study budgets faster and more reliably than traditional Excel-based methods.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
